ArticleThe British journal of dermatology2020

Clinical response correlates with 4-week postinjection ustekinumab concentrations in patients with moderate-to-severe psoriasis.

N Van den Berghe et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.